CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases. Chevalier, K., Genin, M., Jean, T. P., Avouac, J., Flipo, R., Georgin-Lavialle, S., El Mahou, S., Pertuiset, E., Pham, T., Servettaz, A., Marotte, H., Domont, F., Chazerain, P., Devaux, M., Mekinian, A., Sellam, J., Fautrel, B., Rouzaud, D., Ebstein, E., Costedoat-Chalumeau, N., Richez, C., Hachulla, E., Mariette, X., & Seror, R. Frontiers in Medicine, March, 2023. Publisher: Frontiers![CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex \textlesssec\textgreater\textlesstitle\textgreaterIntroduction\textless/title\textgreater\textlessp\textgreaterAutoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.\textless/p\textgreater\textless/sec\textgreater\textlesssec\textgreater\textlesstitle\textgreaterMaterials and methods\textless/title\textgreater\textlessp\textgreaterTwo databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case–control study within the EDS database to compare AIRD cases and non-AIRD controls.\textless/p\textgreater\textless/sec\textgreater\textlesssec\textgreater\textlesstitle\textgreaterResults\textless/title\textgreater\textlessp\textgreaterAmong 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08–1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68–1.81)].\textless/p\textgreater\textless/sec\textgreater\textlesssec\textgreater\textlesstitle\textgreaterConclusion\textless/title\textgreater\textlessp\textgreaterIn this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.\textless/p\textgreater\textless/sec\textgreater
@article{chevalier_covaid_2023,
title = {{CovAID}: {Identification} of factors associated with severe {COVID}-19 in patients with inflammatory rheumatism or autoimmune diseases},
volume = {10},
issn = {2296-858X},
shorttitle = {{CovAID}},
url = {https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1152587/full},
doi = {10.3389/fmed.2023.1152587},
abstract = {{\textless}sec{\textgreater}{\textless}title{\textgreater}Introduction{\textless}/title{\textgreater}{\textless}p{\textgreater}Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.{\textless}/p{\textgreater}{\textless}/sec{\textgreater}{\textless}sec{\textgreater}{\textless}title{\textgreater}Materials and methods{\textless}/title{\textgreater}{\textless}p{\textgreater}Two databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case–control study within the EDS database to compare AIRD cases and non-AIRD controls.{\textless}/p{\textgreater}{\textless}/sec{\textgreater}{\textless}sec{\textgreater}{\textless}title{\textgreater}Results{\textless}/title{\textgreater}{\textless}p{\textgreater}Among 1,213 patients, 195 (16.1\%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08–1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68–1.81)].{\textless}/p{\textgreater}{\textless}/sec{\textgreater}{\textless}sec{\textgreater}{\textless}title{\textgreater}Conclusion{\textless}/title{\textgreater}{\textless}p{\textgreater}In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.{\textless}/p{\textgreater}{\textless}/sec{\textgreater}},
language = {English},
urldate = {2025-03-26},
journal = {Frontiers in Medicine},
author = {Chevalier, Kevin and Genin, Michaël and Jean, Thomas Petit and Avouac, Jerôme and Flipo, Rene-Marc and Georgin-Lavialle, Sophie and El Mahou, Soumaya and Pertuiset, Edouard and Pham, Thao and Servettaz, Amelie and Marotte, Hubert and Domont, Fanny and Chazerain, Pascal and Devaux, Mathilde and Mekinian, Arsene and Sellam, Jérémie and Fautrel, Bruno and Rouzaud, Diane and Ebstein, Esther and Costedoat-Chalumeau, Nathalie and Richez, Christophe and Hachulla, Eric and Mariette, Xavier and Seror, Raphaèle},
month = mar,
year = {2023},
note = {Publisher: Frontiers},
keywords = {COVID-19, Inflammatory rheumatic diseases, Vasculitis, auto-immune disease, lupus, rheumatic and muscoluskeletal disease, rituximab},
}
Downloads: 0
{"_id":"s5a9MHEwsrezTEBrG","bibbaseid":"chevalier-genin-jean-avouac-flipo-georginlavialle-elmahou-pertuiset-etal-covaididentificationoffactorsassociatedwithseverecovid19inpatientswithinflammatoryrheumatismorautoimmunediseases-2023","author_short":["Chevalier, K.","Genin, M.","Jean, T. P.","Avouac, J.","Flipo, R.","Georgin-Lavialle, S.","El Mahou, S.","Pertuiset, E.","Pham, T.","Servettaz, A.","Marotte, H.","Domont, F.","Chazerain, P.","Devaux, M.","Mekinian, A.","Sellam, J.","Fautrel, B.","Rouzaud, D.","Ebstein, E.","Costedoat-Chalumeau, N.","Richez, C.","Hachulla, E.","Mariette, X.","Seror, R."],"bibdata":{"bibtype":"article","type":"article","title":"CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases","volume":"10","issn":"2296-858X","shorttitle":"CovAID","url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1152587/full","doi":"10.3389/fmed.2023.1152587","abstract":"\\textlesssec\\textgreater\\textlesstitle\\textgreaterIntroduction\\textless/title\\textgreater\\textlessp\\textgreaterAutoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.\\textless/p\\textgreater\\textless/sec\\textgreater\\textlesssec\\textgreater\\textlesstitle\\textgreaterMaterials and methods\\textless/title\\textgreater\\textlessp\\textgreaterTwo databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case–control study within the EDS database to compare AIRD cases and non-AIRD controls.\\textless/p\\textgreater\\textless/sec\\textgreater\\textlesssec\\textgreater\\textlesstitle\\textgreaterResults\\textless/title\\textgreater\\textlessp\\textgreaterAmong 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08–1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68–1.81)].\\textless/p\\textgreater\\textless/sec\\textgreater\\textlesssec\\textgreater\\textlesstitle\\textgreaterConclusion\\textless/title\\textgreater\\textlessp\\textgreaterIn this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.\\textless/p\\textgreater\\textless/sec\\textgreater","language":"English","urldate":"2025-03-26","journal":"Frontiers in Medicine","author":[{"propositions":[],"lastnames":["Chevalier"],"firstnames":["Kevin"],"suffixes":[]},{"propositions":[],"lastnames":["Genin"],"firstnames":["Michaël"],"suffixes":[]},{"propositions":[],"lastnames":["Jean"],"firstnames":["Thomas","Petit"],"suffixes":[]},{"propositions":[],"lastnames":["Avouac"],"firstnames":["Jerôme"],"suffixes":[]},{"propositions":[],"lastnames":["Flipo"],"firstnames":["Rene-Marc"],"suffixes":[]},{"propositions":[],"lastnames":["Georgin-Lavialle"],"firstnames":["Sophie"],"suffixes":[]},{"propositions":[],"lastnames":["El","Mahou"],"firstnames":["Soumaya"],"suffixes":[]},{"propositions":[],"lastnames":["Pertuiset"],"firstnames":["Edouard"],"suffixes":[]},{"propositions":[],"lastnames":["Pham"],"firstnames":["Thao"],"suffixes":[]},{"propositions":[],"lastnames":["Servettaz"],"firstnames":["Amelie"],"suffixes":[]},{"propositions":[],"lastnames":["Marotte"],"firstnames":["Hubert"],"suffixes":[]},{"propositions":[],"lastnames":["Domont"],"firstnames":["Fanny"],"suffixes":[]},{"propositions":[],"lastnames":["Chazerain"],"firstnames":["Pascal"],"suffixes":[]},{"propositions":[],"lastnames":["Devaux"],"firstnames":["Mathilde"],"suffixes":[]},{"propositions":[],"lastnames":["Mekinian"],"firstnames":["Arsene"],"suffixes":[]},{"propositions":[],"lastnames":["Sellam"],"firstnames":["Jérémie"],"suffixes":[]},{"propositions":[],"lastnames":["Fautrel"],"firstnames":["Bruno"],"suffixes":[]},{"propositions":[],"lastnames":["Rouzaud"],"firstnames":["Diane"],"suffixes":[]},{"propositions":[],"lastnames":["Ebstein"],"firstnames":["Esther"],"suffixes":[]},{"propositions":[],"lastnames":["Costedoat-Chalumeau"],"firstnames":["Nathalie"],"suffixes":[]},{"propositions":[],"lastnames":["Richez"],"firstnames":["Christophe"],"suffixes":[]},{"propositions":[],"lastnames":["Hachulla"],"firstnames":["Eric"],"suffixes":[]},{"propositions":[],"lastnames":["Mariette"],"firstnames":["Xavier"],"suffixes":[]},{"propositions":[],"lastnames":["Seror"],"firstnames":["Raphaèle"],"suffixes":[]}],"month":"March","year":"2023","note":"Publisher: Frontiers","keywords":"COVID-19, Inflammatory rheumatic diseases, Vasculitis, auto-immune disease, lupus, rheumatic and muscoluskeletal disease, rituximab","bibtex":"@article{chevalier_covaid_2023,\n\ttitle = {{CovAID}: {Identification} of factors associated with severe {COVID}-19 in patients with inflammatory rheumatism or autoimmune diseases},\n\tvolume = {10},\n\tissn = {2296-858X},\n\tshorttitle = {{CovAID}},\n\turl = {https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1152587/full},\n\tdoi = {10.3389/fmed.2023.1152587},\n\tabstract = {{\\textless}sec{\\textgreater}{\\textless}title{\\textgreater}Introduction{\\textless}/title{\\textgreater}{\\textless}p{\\textgreater}Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.{\\textless}/p{\\textgreater}{\\textless}/sec{\\textgreater}{\\textless}sec{\\textgreater}{\\textless}title{\\textgreater}Materials and methods{\\textless}/title{\\textgreater}{\\textless}p{\\textgreater}Two databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case–control study within the EDS database to compare AIRD cases and non-AIRD controls.{\\textless}/p{\\textgreater}{\\textless}/sec{\\textgreater}{\\textless}sec{\\textgreater}{\\textless}title{\\textgreater}Results{\\textless}/title{\\textgreater}{\\textless}p{\\textgreater}Among 1,213 patients, 195 (16.1\\%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08–1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68–1.81)].{\\textless}/p{\\textgreater}{\\textless}/sec{\\textgreater}{\\textless}sec{\\textgreater}{\\textless}title{\\textgreater}Conclusion{\\textless}/title{\\textgreater}{\\textless}p{\\textgreater}In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.{\\textless}/p{\\textgreater}{\\textless}/sec{\\textgreater}},\n\tlanguage = {English},\n\turldate = {2025-03-26},\n\tjournal = {Frontiers in Medicine},\n\tauthor = {Chevalier, Kevin and Genin, Michaël and Jean, Thomas Petit and Avouac, Jerôme and Flipo, Rene-Marc and Georgin-Lavialle, Sophie and El Mahou, Soumaya and Pertuiset, Edouard and Pham, Thao and Servettaz, Amelie and Marotte, Hubert and Domont, Fanny and Chazerain, Pascal and Devaux, Mathilde and Mekinian, Arsene and Sellam, Jérémie and Fautrel, Bruno and Rouzaud, Diane and Ebstein, Esther and Costedoat-Chalumeau, Nathalie and Richez, Christophe and Hachulla, Eric and Mariette, Xavier and Seror, Raphaèle},\n\tmonth = mar,\n\tyear = {2023},\n\tnote = {Publisher: Frontiers},\n\tkeywords = {COVID-19, Inflammatory rheumatic diseases, Vasculitis, auto-immune disease, lupus, rheumatic and muscoluskeletal disease, rituximab},\n}\n\n","author_short":["Chevalier, K.","Genin, M.","Jean, T. P.","Avouac, J.","Flipo, R.","Georgin-Lavialle, S.","El Mahou, S.","Pertuiset, E.","Pham, T.","Servettaz, A.","Marotte, H.","Domont, F.","Chazerain, P.","Devaux, M.","Mekinian, A.","Sellam, J.","Fautrel, B.","Rouzaud, D.","Ebstein, E.","Costedoat-Chalumeau, N.","Richez, C.","Hachulla, E.","Mariette, X.","Seror, R."],"key":"chevalier_covaid_2023","id":"chevalier_covaid_2023","bibbaseid":"chevalier-genin-jean-avouac-flipo-georginlavialle-elmahou-pertuiset-etal-covaididentificationoffactorsassociatedwithseverecovid19inpatientswithinflammatoryrheumatismorautoimmunediseases-2023","role":"author","urls":{"Paper":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1152587/full"},"keyword":["COVID-19","Inflammatory rheumatic diseases","Vasculitis","auto-immune disease","lupus","rheumatic and muscoluskeletal disease","rituximab"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/3745736/collections/FPPE6RWQ/items?key=p2PW2qQS497ilCvf8jlSMRGr&format=bibtex&limit=100","dataSources":["32rcJSP2nwdHwCNxn"],"keywords":["covid-19","inflammatory rheumatic diseases","vasculitis","auto-immune disease","lupus","rheumatic and muscoluskeletal disease","rituximab"],"search_terms":["covaid","identification","factors","associated","severe","covid","patients","inflammatory","rheumatism","autoimmune","diseases","chevalier","genin","jean","avouac","flipo","georgin-lavialle","el mahou","pertuiset","pham","servettaz","marotte","domont","chazerain","devaux","mekinian","sellam","fautrel","rouzaud","ebstein","costedoat-chalumeau","richez","hachulla","mariette","seror"],"title":"CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases","year":2023}